Cardinal Health Oncology survey shows oncologists want more training to care for growing number of cancer survivors.
More than 90% of oncologists said social determinants of health (SDoH) such as financial security, access to food and social isolation are significantly impacting outcomes for cancer patients, according to new research from Cardinal Health Specialty Solutions.
The findings-which are collected from more than 160 oncologists through web-based surveys from February to April this year-provide important insights at a time when the impact of social and economic factors on health are being examined more closely, as a result of the COVID-19 pandemic.
These findings were recently released in the seventh edition of Oncology Insights, a research-based report series analyzing the views of more than 160 U.S. oncologists. The edition focuses on the implications of SDoH on cancer treatment and issues related to caring for a growing number of cancer survivors.
Related: Is Healthcare A Social Or Medical Issue? SDoH Make It Both
Two-thirds, or 68%, of the participating oncologists said at least half of their patients are negatively impacted by SDoH. Financial insecurity/lack of health insurance (83%) was by far the most cited barrier for patients according to participating oncologists, with access to transportation (58%) and health literacy (53%) also among the top responses.
In the report, respondents said responsibility for programs to address SDoH falls across all players in the healthcare system, and most (76%) perceive that assistance programs are not readily accessible, while 81% say that they and their staff are constrained in the amount of time they can spend assisting patients with social needs.
“Our survey shows that oncologists believe a patient’s social determinants of health are critically important when it comes to outcomes," said Bruce Feinberg, DO, vice president and CMO of Cardinal Health Specialty Solutions. "Yet addressing social determinants isn’t a simple matter, and oncologists believe that everyone in the healthcare system must play a role in the solution,”
The report also looked at oncologists’ views on supporting the growing numbers of cancer survivors-a good news development that also presents challenges to care. Key findings include:
Cancer’s Reign Over the Drug Development Pipeline Continues| AMCP Nexus 2024
October 18th 2024The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several months and in early 2025, according to Kaelyn Boss, who gave an oncology drug pipeline talk at the 2024 AMCP Nexus meeting this week.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Verastem Begins Submission for Ovarian Cancer Combination
May 24th 2024Verastem is studying the combination of avutometinib and defactinib to treat low-grade serous ovarian cancer in patients with KRAS-mutations. The company plans to complete the new drug application in the second half of this year.
Read More